OmniAb (OABI) Enterprise Value (2021 - 2026)
OmniAb (OABI) reported Enterprise Value of -$43.0 million for Q1 2026, up 1.44% year-over-year from -$42.4 million in Q1 2025, and up 11.56% on a QoQ basis from -$48.6 million in Q4 2025.
OmniAb (OABI) has 6 years of Enterprise Value data on file, last reported at -$43.0 million in Q1 2026.
- Quarterly Enterprise Value rose 1.44% year-over-year to -$43.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.0 million (up 1.44% YoY) and the FY2025 annual result came in at -$48.6 million, up 1.76% from the prior year.
- Enterprise Value rose to -$43.0 million in Q1 2026 per OABI's latest filing, from -$48.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$19847.0 in Q3 2022 and bottomed at -$113.6 million in Q1 2023.
- The 5-year median for Enterprise Value is -$57.2 million (2024), against an average of -$56.5 million.
- The widest annual swing landed in 2022, when Enterprise Value soared 94.52%; it then sank 486764.51% in 2023.
- Tracing OABI's Enterprise Value over 5 years: stood at -$88.3 million in 2022, then climbed by 1.45% to -$87.0 million in 2023, then soared by 43.15% to -$49.5 million in 2024, then increased by 1.76% to -$48.6 million in 2025, then rose by 11.56% to -$43.0 million in 2026.
- Per Business Quant, the three latest OABI Enterprise Value figures stand at -$43.0 million (Q1 2026), -$48.6 million (Q4 2025), and -$59.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -42.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.97 Mn |
| Dec 31, 2025 | -48.58 Mn |
| Sep 30, 2025 | -59.50 Mn |
| Jun 30, 2025 | -41.62 Mn |
| Mar 31, 2025 | -43.60 Mn |
| Dec 31, 2024 | -49.45 Mn |
| Sep 30, 2024 | -59.38 Mn |
| Jun 30, 2024 | -57.23 Mn |
| Mar 31, 2024 | -69.01 Mn |
| Dec 31, 2023 | -86.98 Mn |
| Sep 30, 2023 | -96.63 Mn |
| Jun 30, 2023 | -103.15 Mn |
| Mar 31, 2023 | -113.61 Mn |
| Dec 31, 2022 | -88.27 Mn |
| Sep 30, 2022 | -19,847.00 |
| Jun 30, 2022 | -159,194.00 |
| Mar 31, 2022 | -434,629.00 |
| Sep 30, 2021 | -362,203.00 |
| Jun 30, 2021 | -36,145.00 |